WeVote
Log In

Bill

Bill

A 9119

Permits licensed pharmacists to prescribe and order certain medications for the purposes of inducing abortion or expelling a miscarriage

2025 Regular Session Introduced by Amy Paulin and 1 co-sponsor

Authorizes licensed pharmacists to prescribe or order certain medications to induce abortion or expel a miscarriage, expanding access and requiring standards and oversight.

REFERRED TO HIGHER EDUCATION
0
WeVote Research Nonpartisan
Bill Summary · A 9119

Summary of New York Bill A 9119 (Introduced 2025)

Overview

  • Bill number: A 9119
  • Title: Permits licensed pharmacists to prescribe and order certain medications for the purposes of inducing abortion or expelling a miscarriage
  • Sponsor: Amy Paulin (primary)
  • Status: Referred to Higher Education (introduced and referred on 2025-09-26)
  • Related companion: S 8593 (Senate)

Purpose and Intent

The bill would authorize licensed pharmacists to prescribe and order certain medications specifically for:
- inducing abortion, and/or
- expelling a miscarriage.

The core aim appears to be expanding pharmacist-provided medication access for abortion care and miscarriage management, thereby broadening routes for patients to obtain relevant medications through pharmacy channels.

Key Provisions (as Introduced)

Note: The full text with exact definitions and requirements would be in the bill language. The following reflects the described scope and typical components of this policy area; consult the enacted text for precise details.

  • Authority granted to pharmacists: Licensed pharmacists would be authorized to prescribe and/or order medications that are used for abortion and/or miscarriage expulsion.
  • Scope of medications: The bill covers “certain medications” designated for these purposes. The specific medications and any related dosing, administration, or monitoring protocols would be defined in the bill.
  • Professional requirements: The authorization would apply to pharmacists who are properly licensed; the bill would likely specify standards, protocols, or conditions under which prescribing/ordering may occur (e.g., patient evaluation, informed consent, eligibility criteria, follow-up).
  • Oversight and standards: Potential references to required protocols, recordkeeping, and coordination with other healthcare providers to ensure continuity of care.
  • Access and access-related considerations: The policy intent often includes expanding timely access to medication-based abortion and miscarriage care, particularly in settings with limited physician availability.

Affected Parties and Impacts

  • Primary beneficiaries: Individuals seeking medication-based abortion or management of miscarriage who would have expanded access points via licensed pharmacists.
  • Pharmacists and pharmacy practice: Pharmacists would assume prescribing/ordering responsibilities for specific medications, subject to regulatory standards.
  • Healthcare system: Possible shifts in how patients access abortion-related medications; potential need for interprofessional coordination and referral pathways.
  • Public health and safety: Emphasis on ensuring safe, appropriate use through defined protocols and oversight.

Procedural and Timeline Details

  • Introduction date: September 26, 2025
  • Current status: Referred to Higher Education committee
  • Legislative path: As a bill introduced in the Assembly, it would progress through committee hearings, potential amendments, and then floor consideration. A companion measure exists in the Senate (S 8593), which may influence cross-chamber considerations and alignment.

Additional Context

  • Companion bill: S 8593 (Senate) – indicates parallel or harmonizing legislation in the Senate.
  • Specifics such as exact medication lists, dosing guidelines, training requirements, patient consent, recordkeeping, and enforcement mechanisms would be detailed in the final bill text.

Next Steps for Readers

  • Monitor the Higher Education committee for hearings or amendments.
  • Compare Assembly A 9119 with its Senate companion S 8593 to understand aligned provisions.
  • Review the bill text upon committee release to see definitions, clinical guidelines, and regulatory requirements.

Note: This summary reflects the introduced bill as of 2025-09-26. For precise language and enforceable provisions, consult the official bill text and any amended versions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.